TWI922768B - 包含cdk4抑制劑之用於治療癌症之方法及給藥方案 - Google Patents

包含cdk4抑制劑之用於治療癌症之方法及給藥方案

Info

Publication number
TWI922768B
TWI922768B TW111146137A TW111146137A TWI922768B TW I922768 B TWI922768 B TW I922768B TW 111146137 A TW111146137 A TW 111146137A TW 111146137 A TW111146137 A TW 111146137A TW I922768 B TWI922768 B TW I922768B
Authority
TW
Taiwan
Prior art keywords
cancer
approximately
treatment
administered
individual
Prior art date
Application number
TW111146137A
Other languages
English (en)
Chinese (zh)
Other versions
TW202329970A (zh
Inventor
敦敦 林
靜 楊
Original Assignee
美商輝瑞大藥廠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商輝瑞大藥廠 filed Critical 美商輝瑞大藥廠
Publication of TW202329970A publication Critical patent/TW202329970A/zh
Application granted granted Critical
Publication of TWI922768B publication Critical patent/TWI922768B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111146137A 2021-12-02 2022-12-01 包含cdk4抑制劑之用於治療癌症之方法及給藥方案 TWI922768B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163285320P 2021-12-02 2021-12-02
US63/285,320 2021-12-02
US202263382346P 2022-11-04 2022-11-04
US63/382,346 2022-11-04
US202263383969P 2022-11-16 2022-11-16
US63/383,969 2022-11-16

Publications (2)

Publication Number Publication Date
TW202329970A TW202329970A (zh) 2023-08-01
TWI922768B true TWI922768B (zh) 2026-04-21

Family

ID=84440018

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111146137A TWI922768B (zh) 2021-12-02 2022-12-01 包含cdk4抑制劑之用於治療癌症之方法及給藥方案

Country Status (10)

Country Link
US (1) US20250041298A1 (cg-RX-API-DMAC7.html)
EP (1) EP4440576A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024542633A (cg-RX-API-DMAC7.html)
KR (1) KR20240112931A (cg-RX-API-DMAC7.html)
AU (1) AU2022400308B2 (cg-RX-API-DMAC7.html)
CA (1) CA3240993A1 (cg-RX-API-DMAC7.html)
IL (1) IL312650A (cg-RX-API-DMAC7.html)
MX (1) MX2024006678A (cg-RX-API-DMAC7.html)
TW (1) TWI922768B (cg-RX-API-DMAC7.html)
WO (1) WO2023100070A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024201340A1 (en) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof
KR20250164842A (ko) 2023-03-30 2025-11-25 화이자 인코포레이티드 Kat6a 억제제에 의한 치료를 위한 예측 바이오마커로서의 kat6a 및 이의 치료 방법
EP4719405A1 (en) 2023-06-02 2026-04-08 Pfizer Inc. Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
WO2026133192A1 (en) * 2024-12-20 2026-06-25 Pfizer Inc. Combination therapies using cdk4 inhibitors with pd-1 axis binding antagonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200354350A1 (en) * 2018-04-26 2020-11-12 Pfizer Inc. Cyclin dependent kinase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4772247A2 (en) * 2013-08-14 2026-07-08 Novartis AG Combination therapy comprising ribociclib and fulvestrant for the treatment of cancer
WO2020157709A1 (en) * 2019-02-01 2020-08-06 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
PT4181920T (pt) * 2020-07-15 2025-11-04 Ctxt Pty Ltd Inibidor de kat6 e combinações para o tratamento do cancro da mama
CN116322693A (zh) * 2020-08-13 2023-06-23 辉瑞公司 组合疗法
MX2023003054A (es) * 2020-09-15 2023-04-05 Pfizer Formas solidas de un inhibidor de cdk4.
EP4288057A4 (en) * 2021-02-05 2025-03-12 Verastem, Inc. Combination therapy for treating abnormal cell growth

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200354350A1 (en) * 2018-04-26 2020-11-12 Pfizer Inc. Cyclin dependent kinase inhibitors

Also Published As

Publication number Publication date
MX2024006678A (es) 2024-06-19
IL312650A (en) 2024-07-01
AU2022400308B2 (en) 2026-02-12
JP2024542633A (ja) 2024-11-15
KR20240112931A (ko) 2024-07-19
EP4440576A1 (en) 2024-10-09
AU2022400308A1 (en) 2024-05-16
CA3240993A1 (en) 2023-06-08
TW202329970A (zh) 2023-08-01
WO2023100070A1 (en) 2023-06-08
US20250041298A1 (en) 2025-02-06

Similar Documents

Publication Publication Date Title
CN108024541B (zh) 用于治疗癌症的方法
AU2022400308B2 (en) Cdk4 inhibitor for the treatment of cancer
EP3076972B1 (en) Cancer treatment with combination of plinabulin and taxane
US12427142B2 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl[oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid
EP4322941A1 (en) Combination comprising ribociclib and amcenestrant
TW202302084A (zh) 以安森司坦和帕博西尼治療乳癌
TW202329946A (zh) 用於治療癌症之方法及包含cdk2抑制劑之給藥方案
JP2024539476A5 (cg-RX-API-DMAC7.html)
EP4489756A1 (en) Methods of treating small cell lung cancer
CN118338901A (zh) 用于治疗癌症的cdk4抑制剂
BR112021014820A2 (pt) Uso da composição contendo inibidor de cdk4/6 em combinação com anastrozol na preparação de medicamento para tratar doenças tumorais
WO2023281413A1 (en) Methods and dosing regimens comprising pf-06873600 for the treatment of cancer
Kim et al. A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer
HK40110657A (en) Cdk4 inhibitor for the treatment of cancer
RU2854294C2 (ru) Ингибитор cdk4 для лечения рака
WO2024246824A1 (en) Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
TWI922738B (zh) 化合物或其藥劑學上可接受的鹽用於製造實性瘤治療用醫藥組成物之用途
Yang et al. HS-10296–a novel third generation EGFR tyrosine kinase inhibitor: results of the first-in-human phase 1 trial in patients with previously treated EGFR mutant advanced non-small-cell lung cancer
HK40082294A (en) Uses of mitoxantrone hydrochloride liposome
WO2026092748A1 (zh) 雄性激素合成抑制剂与parp抑制剂联合用于治疗前列腺癌
HK40066922A (en) Treatment of breast cancer using combination therapies comprising an atp competitive akt inhibitor, a cdk4/6 inhibitor, and fulvestrant
CN120035437A (zh) 用于治疗EGFR突变癌症的N-(1-((R)-1-丙烯酰基氮杂环庚烷-3-基)-7-氯-6-(((R)-四氢呋喃-3-基)氧基)-1H-苯并[d]咪唑-2-基)-2-甲基异烟酰胺(NX-019)
WO2026021478A1 (zh) Ar降解剂与parp1抑制剂联合用于治疗前列腺癌的方法
CN117580572A (zh) 用安森司坦和帕博西尼治疗乳腺癌
HK1229712B (en) Cancer treatment with combination of plinabulin and taxane